Ketamine, psychedelics, GHB: is the US falling out of love with cocaine?
Drug use patterns in the United States appear to be shifting, with alternative substances like ketamine, psychedelics, and GHB gaining attention while cocaine's prominence may be declining. The Trump administration has issued an order to accelerate review of psychedelic compounds for therapeutic purposes, particularly ibogaine. This development has generated coverage across the political spectrum, with different outlets emphasizing distinct aspects of the policy and broader drug landscape.
Left-leaning coverage examines the broader cultural and chemical shift in drug consumption patterns, positioning the story within a wider context of changing substance use trends across American society.
Center outlets focus on the specific policy mechanism—the Trump order and its potential to expedite regulatory review of compounds like ibogaine—treating it as a discrete policy development with practical implications.
Right-leaning sources emphasize the irony and political narrative of Trump advancing psychedelic research more aggressively than predecessors, framing it as a counterintuitive policy achievement that challenges stereotypes about conservative drug policy.
Key Differences
- Right outlets focus heavily on Trump's role and the political irony, while left coverage emphasizes broader epidemiological trends in drug use patterns
- Center coverage treats this primarily as a regulatory/policy story, whereas right outlets frame it as a narrative about Trump's unexpected alignment with psychedelic research advocates
- Right-leaning sources dedicate multiple pieces to the same policy, suggesting sustained interest in the political angle that other outlets don't replicate
Left(1)
Center(1)
Right(3)
ReasonAApr 20, 1:31 PM
Trump Signs Psychedelics Order
Plus: ship seizures, the best free bread in America, and more...
ReasonAApr 20, 7:40 PM
The Promise and Limits of Trump's Psychedelic Therapy Order
The president's facilitation of research and FDA review could help make psychedelics available to approved patients. But what about everyone else?
ReasonAApr 21, 10:12 PM
The Least-Psychedelic President in History Supports Psychedelic Research More Than Any of His Predecessors
Donald Trump is an unlikely but powerful champion of drug reform.
Get this analysis in your inbox
The Daily Spectrum: one email, three perspectives on the day's biggest stories.
Free forever. Unsubscribe anytime. No spam.